Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rein TherapeuticsRNTX -3.15%30 3-Year EBITDA Growth Rate is 47.80% as of Jun. 2026, which is 31% above its 10-year median of 36.55. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Rein Therapeutics ranks better than 84.38% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 47.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 30.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rein Therapeutics was 48.20% per year. The lowest was -36.00% per year. And the median was 36.55% per year.
Rein Therapeutics (NAS:RNTX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rein Therapeutics 3-Year EBITDA Growth Rate Related Terms
RNTX vs ALPS, HYFT, PMVP: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Rein Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rein Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rein Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rein Therapeutics's 3-Year EBITDA Growth Rate falls into.
Rein Therapeutics 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 47.80% mean?
Rein Therapeutics (RNTX) has a 3-Year EBITDA Growth Rate of 47.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rein Therapeutics and its competitors. This is 31% above median its historical median of 36.55. According to the industry distribution chart, Rein Therapeutics ranks #176 out of 1127 companies in the Biotechnology industry, placing it in the top 15.6%.
Is Rein Therapeutics' 3-Year EBITDA Growth Rate too high?
Rein Therapeutics' current 3-Year EBITDA Growth Rate of 47.80% is 31% above median its 10-year median of 36.55. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Rein Therapeutics' value of 47.80% is 227.4% above this industry median. Based on the distribution chart, Rein Therapeutics ranks #176 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' 3-Year EBITDA Growth Rate compare to ALPS and HYFT?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #176 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Rein Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Rein Therapeutics' value of 47.80% is 227.4% above this benchmark. While the company's 10-year median is 36.55 vs. the industry median of 14.60, Rein Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rein Therapeutics's current 3-Year EBITDA Growth Rate of 47.80% is 227.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rein Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rein Therapeutics's current 3-Year EBITDA Growth Rate is 47.80%, which is 31% above median its own 10-year median of 36.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current 3-Year EBITDA Growth Rate of 47.80%. The current 3-Year EBITDA Growth Rate is 47.80%, which is 31% above median its 10-year median of 36.55 and 227.4% above the Biotechnology industry median of 14.60. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current 3-Year EBITDA Growth Rate is 47.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score
Get the complete analysis for RNTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNTX has been successfully added to your 
